Lisata Therapeutics Inc. (LSTA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Lisata Therapeutics Inc. (LSTA) has a cash flow conversion efficiency ratio of -0.332x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.65 Million) by net assets ($7.99 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see LSTA market cap overview for the company's overall valuation and market capitalisation.
Lisata Therapeutics Inc. - Cash Flow Conversion Efficiency Trend (1993–2025)
This chart illustrates how Lisata Therapeutics Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
Lisata Therapeutics Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Lisata Therapeutics Inc. ranked by their cash flow conversion efficiency. Explore LSTA cash to earnings ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Mobix Labs Inc
NASDAQ:MOBX
|
-0.913x |
|
Pimpinan Eshan Bhd
KLSE:5622
|
-0.015x |
|
Novatech Industries SA
PA:MLNOV
|
N/A |
|
Menteng Heritage Realty Tbk PT
JK:HRME
|
-0.001x |
|
Immo Mcc NV
BR:MCC
|
N/A |
|
Hoth Therapeutics Inc
NASDAQ:HOTH
|
-0.362x |
|
HPMT Holdings Bhd
KLSE:5291
|
-0.045x |
|
Starr Peak Exploration Ltd
V:STE
|
-0.013x |
Annual Cash Flow Conversion Efficiency for Lisata Therapeutics Inc. (1993–2025)
The table below shows the annual cash flow conversion efficiency of Lisata Therapeutics Inc. from 1993 to 2025. View LSTA stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $14.60 Million | $-15.95 Million | -1.092x | -65.45% |
| 2024-12-31 | $29.32 Million | $-19.36 Million | -0.660x | -57.85% |
| 2023-12-31 | $47.89 Million | $-20.03 Million | -0.418x | -31.04% |
| 2022-12-31 | $66.32 Million | $-21.17 Million | -0.319x | -32.01% |
| 2021-12-31 | $92.00 Million | $-22.25 Million | -0.242x | +11.64% |
| 2020-12-31 | $32.24 Million | $-8.82 Million | -0.274x | +70.21% |
| 2019-12-31 | $20.55 Million | $-18.88 Million | -0.919x | -72.17% |
| 2018-12-31 | $37.45 Million | $-19.99 Million | -0.534x | -28.29% |
| 2017-12-31 | $50.19 Million | $-20.88 Million | -0.416x | +92.85% |
| 2016-12-31 | $4.07 Million | $-23.67 Million | -5.820x | -245.19% |
| 2015-12-31 | $23.28 Million | $-39.26 Million | -1.686x | -108.80% |
| 2014-12-31 | $58.07 Million | $-46.90 Million | -0.808x | -84.81% |
| 2013-12-31 | $62.03 Million | $-27.10 Million | -0.437x | -3.52% |
| 2012-12-31 | $32.82 Million | $-13.85 Million | -0.422x | -61.61% |
| 2011-12-31 | $80.13 Million | $-20.93 Million | -0.261x | -166.47% |
| 2010-12-31 | $86.49 Million | $-8.48 Million | -0.098x | +32.47% |
| 2009-12-31 | $59.59 Million | $-8.65 Million | -0.145x | +97.35% |
| 2008-12-31 | $863.18K | $-4.73 Million | -5.482x | -196.46% |
| 2007-12-31 | $3.32 Million | $-6.13 Million | -1.849x | +85.16% |
| 2006-12-31 | $292.11K | $-3.64 Million | -12.457x | -2814.98% |
| 2005-12-31 | $-1.82 Million | $-834.00K | 0.459x | -39.28% |
| 2004-12-31 | $-1.93 Million | $-1.46 Million | 0.756x | +11.11% |
| 2003-12-31 | $-1.50 Million | $-1.02 Million | 0.680x | +155.73% |
| 2002-12-31 | $-823.89K | $1.01 Million | -1.220x | -21.99% |
| 2001-12-31 | $373.73K | $-373.84K | -1.000x | -58.51% |
| 2000-12-31 | $3.13 Million | $-1.98 Million | -0.631x | -579.82% |
| 1999-12-31 | $3.92 Million | $-364.12K | -0.093x | -110.60% |
| 1998-12-31 | $-307.81K | $-269.60K | 0.876x | +87.60% |
| 1996-12-31 | $-651.71K | $-304.27K | 0.467x | -82.23% |
| 1995-12-31 | $-319.11K | $-838.44K | 2.627x | +807.11% |
| 1994-12-31 | $-2.90 Million | $-840.00K | 0.290x | -- |
| 1993-12-31 | $0.00 | $470.00K | x | -- |
About Lisata Therapeutics Inc.
Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product is certepetide, which is in Phase 2 clinical studies for the treatment of solid tumors, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal ca… Read more